{
    "eid": "2-s2.0-85101810675",
    "title": "Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines",
    "cover-date": "2021-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Antituberculosis drugs",
        "APASL",
        "Consensus",
        "DILI",
        "Drug-induced liver injury",
        "Guidelines",
        "Hepatotoxicity",
        "Medications",
        "Monitoring",
        "Risk factors",
        "Traditional and complimentary medicine",
        "Treatment",
        "Tuberculosis"
    ],
    "authors": [
        "Harshad Devarbhavi",
        "Guruprasad Aithal",
        "Sombat Treeprasertsuk",
        "Hajime Takikawa",
        "Yimin Mao",
        "Saggere M. Shasthry",
        "Saeed Hamid",
        "Soek Siam Tan",
        "Cyriac Abby Philips",
        "Jacob George",
        "Wasim Jafri",
        "Shiv K. Sarin"
    ],
    "citedby-count": 63,
    "ref-count": 183,
    "ref-list": [
        "An official ATS statement: hepatotoxicity of antituberculosis therapy",
        "Incidence and etiology of drug-induced liver injury in Mainland China",
        "Ashwagandha-induced liver injury: a case series from Iceland and the US drug-induced liver injury network",
        "Incidence of drug-induced hepatic injuries: a French population-based study",
        "Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland",
        "A prospective nationwide study of drug-induced liver injury in Korea",
        "Case definition and phenotype standardization in drug-induced liver injury",
        "Grading quality of evidence and strength of recommendations",
        "Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005",
        "Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries",
        "Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex",
        "Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study",
        "Antituberculosis drug-induced hepatotoxicity: concise up-to-date review",
        "Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic",
        "Valproic acid hepatic fatalities. III. US experience since 1986",
        "Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis",
        "Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI)",
        "Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles",
        "A missense variant in PTPN22 is a risk factor for drug-induced liver injury",
        "Effects of alcohol on other hepatotoxins",
        "Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial",
        "The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer",
        "Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection",
        "Risk factors for idiosyncratic drug-induced liver injury",
        "Are patients with elevated liver tests at increased risk of drug-induced liver injury?",
        "Rifampin-lnduced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin",
        "Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus",
        "Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C",
        "Liver injury from herbals and dietary supplements in the US drug-induced liver injury network",
        "Dietary supplement use in the United States, 2003\u20132006",
        "Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period",
        "Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury",
        "Characteristics of liver injury in drug-induced systemic hypersensitivity reactions",
        "Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents",
        "Drug-induced liver injury associated with stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases",
        "Anticonvulsant hypersensitivity syndrome: an update",
        "Criteria of drug-induced liver disorders. Report of an international consensus meeting",
        "Drug-related hepatotoxicity",
        "Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study",
        "Drug-induced autoimmune hepatitis: clinical characteristics and prognosis",
        "The natural history of histologically proved drug induced liver disease",
        "Features of autoimmune hepatitis in patients with drug-induced liver injury",
        "Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis",
        "Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases",
        "Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry",
        "Epidemiology and individual susceptibility to adverse drug reactions affecting the liver",
        "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention",
        "End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome",
        "Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use",
        "Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer",
        "Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry",
        "The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity",
        "Hy's law: predicting serious hepatotoxicity",
        "Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States",
        "Docetaxel induced sclerosing cholangitis",
        "Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?",
        "Histological patterns in drug-induced liver disease",
        "Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations",
        "Agreement of expert judgment in causality assessment of adverse drug reactions",
        "Accuracy of hepatic adverse drug reaction reporting in one English health region",
        "Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge",
        "ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury",
        "EASL clinical practice guidelines: drug-induced liver injury",
        "Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis",
        "Comparison of two clinical scales for causality assessment in hepatotoxicity",
        "Tools for causality assessment in drug-induced liver disease",
        "Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method",
        "A proposal of the diagnostic scale of drug-induced liver injury",
        "Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 workshop",
        "Epidemiology of domestically acquired hepatitis E virus infection in Japan: assessment of the nationally reported surveillance data, 2007\u20132013",
        "A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the council for international organizations of medical sciences/the roussel uclaf causality assessment method scale",
        "Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response",
        "Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset",
        "Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review",
        "Drug rechallenge following drug-induced liver injury",
        "Drug-induced liver injury following positive drug rechallenge",
        "Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity",
        "The management of anti-tuberculosis drug-induced hepatotoxicity",
        "Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients",
        "HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin",
        "Of potions, poisons, polygonum and pre-emptive polymorphism",
        "Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications",
        "Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice",
        "EASL clinical practice guidelines: autoimmune hepatitis",
        "International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis",
        "Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort",
        "Outcome and prognostic markers in severe drug-induced liver disease",
        "Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury",
        "Liver damage from flucloxacillin, cloxacillin and dicloxacillin",
        "The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice",
        "Clinical features, diagnosis, and natural history of drug-induced liver injury",
        "Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality",
        "Leflunomide: a review of its use in active rheumatoid arthritis",
        "Effect of l-carnitine treatment for valproate-induced hepatotoxicity",
        "Carnitine in the treatment of valproic acid-induced toxicity",
        "Two cases of valproic acid poisoning treated with l-carnitine",
        "Levocarnitine for the treatment of valproic acid-induced hyperammonemic encephalopathy in children: the experience of a large, Tertiary Care Pediatric Hospital and a Poison Center",
        "Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure",
        "N-Acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury",
        "Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?",
        "Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: a case report",
        "Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man",
        "Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury",
        "Cholestatic liver injury induced by pembrolizumab in a patient with lung adenocarcinoma",
        "Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury",
        "Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study",
        "Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls",
        "Drug-induced autoimmune-like hepatitis",
        "Liver damage related to immune checkpoint inhibitors",
        "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States",
        "Risk factors, clinical presentation, and outcomes in overdose with acetaminophen alone or with combination products: results from the acute liver failure study group",
        "Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury",
        "Drug-induced acute liver failure: results of a US multicenter, prospective study",
        "2018 annual report of the European Liver Transplant Registry (ELTR)\u201450-year evolution of liver transplantation",
        "Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial",
        "High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial",
        "Interventions for paracetamol (acetaminophen) overdose",
        "Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival",
        "Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure",
        "Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure",
        "Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial",
        "Evidence-based liver chemistry monitoring in drug development",
        "Chapter 21\u2014mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs",
        "Drug-induced liver injury: an overview over the most critical compounds",
        "Hepatotoxicity with combination of vemurafenib and ipilimumab",
        "Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications",
        "Liver injury from herbal and dietary supplements",
        "HLA-B* 35: 01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans",
        "Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum",
        "Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan",
        "Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature",
        "updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome",
        "Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration",
        "CSH guidelines for the diagnosis and treatment of drug-induced liver injury",
        "Pyrrolizidine alkaloid-protein adducts: potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure",
        "Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial",
        "Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients",
        "Herbal and dietary supplement-induced liver injuries in the Spanish DILI registry",
        "Ayurvedic and herbal medicine-induced liver injury: It is time to wake up and take notice",
        "Indian traditional ayurvedic system of medicine and nutritional supplementation",
        "Utilization of alternative systems of medicine as health care services in India: evidence on AYUSH care from NSS 2014",
        "Causes, clinical features, outcomes and predictors of mortality from a nationwide prospective study of drug-induced liver injury",
        "Drug-induced acute-on-chronic liver failure in Asian patients",
        "Clinical outcomes, histopathologic patterns and chemical analysis of ayurveda and herbal medicine associated with severe liver injury\u2014a single center experience from South India",
        "A Single-center experience on outcomes of complementary and alternative medicine use among patients with cirrhosis",
        "Ayurvedic research and methodology: present status and future strategies",
        "Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)",
        "RUCAM in drug and herb induced liver injury: the update",
        "Complementary and alternative medicine-related drug-induced liver injury in Asia",
        "Important elements for the diagnosis of drug-induced liver injury",
        "Severe hepatotoxicity by Indian ayurvedic herbal products: a structured causality assessment",
        "Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice",
        "Death and liver transplantation within two years of onset of drug-induced liver injury",
        "Severe liver injury due to herbal and dietary supplements and the role of liver transplantation",
        "Landscape of liver injury from herbal and dietary supplements in Europe, Latin America, and Asia",
        "Outcomes and toxicology of herbal drugs in alcoholic hepatitis\u2014a single center experience from India",
        "Ayurvedic drugs in case: claims, evidence, regulations and ethics",
        "Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study",
        "A comparison between two strategies for monitoring hepatic function during antituberculous therapy",
        "Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury",
        "Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients",
        "Acute liver failure induced by anti-infectious drugs: causes and management",
        "The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents",
        "Drug induced liver injury at a tertiary hospital in india: etiology, clinical features and predictors of mortality",
        "Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity",
        "Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis",
        "Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury",
        "Combined 5\u2010hydroxymethylcytosine content of human leucocyte antigen\u2010B and human leucocyte antigen\u2010DQB1 as novel biomarker for anti\u2010tuberculosis drug\u2010induced liver injury",
        "Genetic risk factors in drug-induced liver injury due to isoniazid-containing anti-tuberculosis drug regimens",
        "Hepatotoxicity of antituberculosis drugs",
        "Anti-tuberculosis medication and the liver: dangers and recommendations in management",
        "Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study",
        "Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease\u2014a physiopathological and clinical integrated view",
        "A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease",
        "Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury",
        "Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections",
        "Influence of high body mass index on outcome in acute liver failure"
    ],
    "affiliation": [
        {
            "affiliation-city": "New Delhi",
            "@id": "60107629",
            "affilname": "Institute of Liver and Biliary Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107629",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60082819",
            "affilname": "Shanghai Jiao Tong University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082819",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Karachi",
            "@id": "60067302",
            "affilname": "The Aga Khan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60067302",
            "affiliation-country": "Pakistan"
        },
        {
            "affiliation-city": "Nottingham",
            "@id": "60025016",
            "affilname": "Nottingham University Hospitals NHS Trust",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025016",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Sydney",
            "@id": "60004437",
            "affilname": "Westmead Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004437",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bengaluru",
            "@id": "60004020",
            "affilname": "St. John's Medical College Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004020",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Selangor",
            "@id": "126196916",
            "affilname": "Hospital Selayang",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126196916",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Kochi",
            "@id": "115418372",
            "affilname": "Rajagiri Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115418372",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Tokyo",
            "@id": "101538317",
            "affilname": "School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101538317",
            "affiliation-country": "Japan"
        }
    ],
    "funding": []
}